Interim report

January 1 – September 30, 2015

The third quarter in figures

  • Total net sales amounted to TSEK 995 (818).
  • The loss after tax amounted to TSEK 10,260 (7,935).
  • The loss per share amounted to SEK 1.24 (1.59).
  • The cash flow from current operations was negative in the amount of TSEK 9,669 (9,578).

The 9-months in figures

  • Total net sales amounted to TSEK 2,970 (1,140).
  • The loss after tax amounted to TSEK 30,378 (28,499).
  • The loss per share amounted to SEK 4.71 (5.72).
  • The cash flow from current operations was negative in the amount of TSEK 32,724 (27,787).

Important events during the quarter

  • During the period the high level results from the “Reader-study” in the US were published. The results from the study show that the addition of Nevisense significantly improved the ability of US dermatologists to accurately detect melanoma. The Reader Study is an important requirement of the application process to the US Food and Drug Administration (FDA). With the results from the study, SciBase can now finalize and file its PMA application with the FDA.
  • Pareto Securities has during the period exercised the possibility to, in connection with the initial public offering of SciBase Holding AB (publ) (“SciBase”), carry out stabilization-like transactions. All stabilization-like transactions were carried out between June 2, 2015 and June 10, 2015 and no further stabilization-like transactions will be carried out.

Important events after the end of the period

  • No significant events after the period have been reported.

Financial overview

Oct 1 2014 -
July 1 - Sep 30 Jan 1 - Sep 30 Sep 30 2015 Jan 1 - Dec 31
THE GROUP 2015 2014 2015 2014 Rolling-12 2014
Net sales, SEK ths 995 818 2 970 1 140 3 430 1 600
Gross margin, % 17,6% -42,8% -3,8% -33,9% -8,9% -36,0%
Equity/Asset ratio, % 94,2% 84,4% 94,2% 84,4% 94,2% 78,5%
Net indebtness, multiple 0,06 0,19 0,06 0,19 0,06 0,27
Cash equivalents, SEK ths 147 661 37 176 147 661 37 176 147 661 27 566
Cashflow from operating activities, SEK ths -9 669 -9 578 -32 724 -27 787 -42 014 -37 077
Earnings per share (before and after dilution), SEK* -1,24 -1,59 -4,71 -5,72 -6,68 -7,78
Shareholder's equity per share, SEK* 18,93 8,61 24,31 8,61 25,78 6,55
Average number of shares, 000'* 8 285 4 985 6 451 4 984 6 085 4 984
Number of shares at closing of period, 000'* 8 285 4 985 8 285 4 985 8 285 4 985
Average number of employees 15 12 14 12 14 12

Definitions and a glossary are provided on page 15.

For further information please contact:

Simon Grant, CEO, tele :   46 72 887 43 99

Michael Colérus, CFO, tele : 46 70 341 34 72

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com

Tags:

About Us

SciBase is a Swedish medical technology company founded in 1998 that has developed Nevisense, a point-of-care device for the accurate detection of malignant melanoma. Nevisense has emerged from more than 20 years of research at Karolinska Institute in Stockholm and at SciBase. The device is designed to be provide additional information when evaluating lesions with a suspicion of melanoma. Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The CE-marked system consists of an electrode on a hand-held probe connected to a small portable device performing the analysis and displaying the result. A video describing the Nevisense method is available on: www.scibase.se/en/the-nevisenseproduct and further information is also available on www.scibase.com.

Subscribe

Documents & Links